Previously doing business as Paradigm Gcnetics Inc, in July 2006, Icoria Inc was acquired by Cogenics. The firm operated as Cogenics Icoria, Inc. - subsidiary of Beckman Coulter. Icoria Inc had been a biotechnology company seeking to improve research and development productivity in the agricultural and healthcare industries. The Company used a systems biology approach to understand gene function in the context of biological pathways and to develop assays and biomarkers for molecular diagnostic solutions for life sciences companies. By conducting its research with a gene-to-cell-to-system approach, the Company ensured that it has an accurate and complete understanding of biological systems. Paradigm had focusied on five market opportunities: crop traits, crop protection, green biotechnology, predictive toxicology and biomarker discovery. In March 2005, the firm sold assets relating to its agricultural genomics business to Monsanto Company. Icoria then focused on the discovery, development and commercialization of diagnostics and targeted therapeutics in diabetes, obesity, oncology and other areas of unmet medical need. Icoria's proprietary Gene to Cell to SystemTM approach has four major technology components: gene expression profiling, biochemical profiling phenotypic profiling and pathway informatics.
